LABAs effective in COPD
Use of Long-acting ?2-agonists reduces severe exacerbations in patients with COPD, with no adverse impact on all-cause or respiratory mortality, a meta-analysis shows.
A team of international researchers assessed a total of 27 studies.
LABA treatment reduced severe exacerbations by 22% compared with placebo, although it was associated with significantly more severe exacerbations than tiotropium in moderate to severe disease.
Use of the drugs with inhaled steroids reduced the risk of respiratory death compared with LABAs alone.